Prophylactic CPAP for Late Preterm Infants Born by C-Section to Reduce NICU Admission (PLaNT2)

November 4, 2026 updated by: Edgardo Szyld, Indiana University

Prophylactic CPAP for Late Preterm Infants Born by C-Section to Reduce NICU Admission: A Multicenter Randomized Controlled Trial (PLaNT 2 Study)

The PLaNT 2 study will test whether giving breathing support soon after birth can help late preterm babies born by cesarean section (C-section). The goal is to lower breathing problems and the need for admission to the neonatal intensive care unit (NICU).

Late preterm babies are born a few weeks before their due date. They have a higher risk of breathing problems after birth, especially after a C-section. A recent international pilot study showed promising results with early breathing support in these babies. A larger study is now needed to find out if this approach works.

Continuous positive airway pressure (CPAP) is a common form of breathing support for newborns. It provides gentle air pressure through a mask or nasal prongs. CPAP is usually given after a baby develops breathing problems. PLaNT 2 will test giving CPAP shortly after birth, before breathing problems develop.

The study will include 300 babies born by C-section at 35 to 36 weeks of pregnancy. Babies who are breathing on their own within 5 minutes after birth may take part. The study will randomly assign babies to one of two groups:

  • One group will receive 20 minutes of CPAP shortly after birth.
  • The other group will receive the hospital's usual care. Babies in either group can receive CPAP or other breathing support later if they need it.

The main question is whether early CPAP lowers the number of babies admitted to the NICU for breathing support. Researchers will also look at the need for breathing support after birth. They will study parental stress, bonding between mothers and babies, and exclusive breastfeeding.

If this approach works, it could lower breathing problems and unnecessary NICU admissions. This could allow more babies to stay with their families. CPAP is already available in many hospitals, so this approach could be used in different health care settings around the world. It may also support early bonding, breastfeeding, and family-centered newborn care.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Late preterm infants are at increased risk of respiratory morbidity during the transition from fetal to newborn life. This risk is particularly important among infants born by cesarean section. These infants do not experience some of the physiologic changes associated with labor and vaginal delivery that promote lung fluid clearance and adaptation to air breathing. As a result, respiratory distress is a common reason for neonatal intensive care unit (NICU) admission in this population.

NICU admission may be necessary when an infant requires respiratory support or other intensive care. However, NICU admission also separates infants from their families and may affect early bonding and breastfeeding. Preventing respiratory deterioration before it requires escalation of care could therefore have benefits for both infants and families.

Continuous positive airway pressure (CPAP) is widely used to support newborns who develop respiratory distress. CPAP helps maintain lung expansion and supports breathing without the need for an endotracheal tube. In current practice, CPAP is generally used after signs of respiratory difficulty appear. The PLaNT 2 study evaluates a different approach: providing a brief period of CPAP soon after birth to infants at increased risk, before respiratory distress develops.

Rationale and Preliminary Evidence PLaNT 2 builds on an international, multicenter pilot randomized controlled trial of prophylactic CPAP in spontaneously breathing late preterm infants born by cesarean section. The pilot trial evaluated feasibility, safety, and preliminary evidence of benefit.

A total of 122 infants were enrolled at five centers in the United States, Canada, and Chile, and 115 infants were included in the analysis. No pneumothorax or other serious adverse events were observed in either study group.

The pilot study also showed promising respiratory outcomes. Among the prespecified subgroup of infants born at 35 to 36 weeks of gestation, NICU admission for respiratory reasons occurred in 38% of infants receiving standard care compared with 16% of infants receiving prophylactic CPAP. The need for subsequent respiratory support during the first week was also lower in the prophylactic CPAP group. These findings supported the development of a larger trial focused on infants born at 35 to 36 weeks of gestation.

The pilot was not designed to provide definitive evidence that prophylactic CPAP improves clinical outcomes. PLaNT 2 is designed to answer this question in a larger, international population.

Study Rationale PLaNT 2 is a pragmatic, multicenter, international randomized controlled trial comparing prophylactic CPAP with standard care in late preterm infants born by cesarean section.

The study focuses on infants born at 35 to 36 weeks of gestation because infants born before 35 weeks are routinely admitted to a NICU or special care nursery at many hospitals regardless of their respiratory status. In contrast, infants born at 35 and 36 weeks are not routinely admitted to the NICU. Respiratory problems therefore represent an important and potentially preventable reason for NICU admission in this group.

The intervention is intended to support the infant during the early transition after birth. Rather than waiting for respiratory distress to develop before providing CPAP, the study tests whether a short period of prophylactic CPAP can support lung expansion and respiratory transition before clinically important respiratory problems develop.

The study intervention does not replace standard neonatal care. Infants in either study group may receive CPAP or other respiratory support when clinically indicated. Rescue CPAP is considered part of standard clinical care and is not considered a protocol deviation.

Study Design Families will be approached for informed consent before delivery. Final newborn eligibility will be confirmed after birth.

Because the study evaluates prophylactic CPAP in spontaneously breathing infants, allocation will remain concealed until the clinical team confirms that the infant has established spontaneous breathing within the first 5 minutes after birth. Brief positive-pressure ventilation before spontaneous breathing is established does not by itself make an infant ineligible if spontaneous breathing is subsequently established within this period. Infants who are not spontaneously breathing by 5 minutes will not be randomized and will continue to receive clinically appropriate care.

Participants will be assigned in a 1:1 ratio to prophylactic CPAP or standard care. Randomization will be stratified by participating site and gestational age. Site-specific, sequentially numbered, opaque, sealed envelopes will be used to conceal and implement treatment allocation. Separate envelope sequences will be maintained for the gestational-age strata. For twin pregnancies, one envelope will be used to randomize the pregnancy, and both twins will receive the same study-group assignment.

Infants assigned to the intervention will receive a brief period of prophylactic CPAP beginning shortly after birth. CPAP may be provided at the radiant warmer or while the infant is on the mother's chest when clinically and operationally appropriate. Infants assigned to the control group will receive standard care. Clinical teams in both groups retain full responsibility for the infant's care and may initiate or escalate respiratory support whenever medically indicated.

Assessment of Respiratory Outcomes The primary clinical question is whether prophylactic CPAP lowers NICU admission for respiratory support.

NICU admission practices can differ among hospitals. In addition to recording actual NICU admission, the study therefore includes standardized respiratory assessments after birth. This approach will provide a consistent measure of respiratory status across participating centers.

Respiratory status will be documented at 30 minutes after birth. At 60 minutes, all randomized infants will undergo a standardized respiratory assessment regardless of their location at that time. This includes infants who remain in the delivery room, are with their parent or in a newborn nursery, are receiving transitional care, or have already been admitted to a NICU.

The 60-minute assessment will document oxygen saturation, supplemental oxygen use, respiratory rate, signs of respiratory distress, and respiratory support. Standardized criteria will be used to determine whether an infant meets predefined criteria for NICU admission for respiratory support, independent of the infant's actual location or the local hospital's admission decision. Actual NICU admission for respiratory support will remain the primary clinically relevant outcome.

Respiratory support and other clinical outcomes will also be followed after the initial transition period. These data will help determine whether any early effect of prophylactic CPAP is associated with differences in subsequent respiratory care.

Family-Centered Outcomes PLaNT 2 also examines outcomes that are important to families. Admission of a newborn to the NICU can result in separation from parents during an important period for bonding and breastfeeding. The study will therefore evaluate parental stress, mother-infant bonding, and exclusive breastfeeding in addition to respiratory outcomes.

Parental stress and mother-infant bonding will be assessed using validated measures. Breastfeeding information will also be collected during the study period. These outcomes will help determine whether differences in respiratory illness and NICU admission are associated with meaningful differences in the experience of infants and their families.

Multicenter and International Design PLaNT 2 is designed as a pragmatic trial so that its findings can apply to routine clinical practice. Participating hospitals represent different patient populations, clinical practices, and health care settings.

CPAP is already commonly used in newborn care, and the intervention relies on equipment and clinical skills that are already available at participating centers. The study tests a new preventive use of an established therapy rather than a new drug or device.

If this approach works, it could lower respiratory complications and unnecessary NICU admissions while allowing more newborns to remain with their families. Because the intervention uses existing technology and clinical expertise, the findings could also be relevant to a wide range of health care settings.

Study Type

Interventional

Enrollment (Estimated)

300

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Edgardo Szyld, MD, MSc
  • Phone Number: 267-752-0028
  • Email: eszyld@iu.edu

Study Locations

    • Alberta
      • Edmonton, Alberta, Canada, T5H 3V9
        • Royal Alexandra Hospital
        • Contact:
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile
        • Pontificia Universidad Catolica de Chile
        • Contact:
    • Valencia
      • Valencia, Valencia, Spain, 46026
        • Instituto de Investigacion Sanitaria La Fe
        • Contact:
      • Bristol, United Kingdom, BS10 5NB
    • Alabama
      • Birmingham, Alabama, United States, 35233
        • Women and Infants Center, UAB
        • Contact:
    • California
      • Sacramento, California, United States, 95817
      • San Diego, California, United States, 92123-2700
        • Sharp Mary Birch Hospital for Women & Newborns
        • Contact:
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Riley Hospital
        • Contact:
    • Missouri
      • St Louis, Missouri, United States, 63104
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Children'S Hospital Oklahoma City
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Birju A Shah, MD, MPH
        • Sub-Investigator:
          • LISE DESHEA, PHD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 second to 5 minutes (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Inborn newborns delivered by cesarean section (with or without labor)
  • Gestational age 35⁰⁄₇ to 36⁶⁄₇ weeks by best obstetrical estimate
  • Spontaneously breathing within 5 minutes after birth.

Exclusion Criteria:

  • Major congenital anomalies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prophylactic CPAP

Participants assigned to this arm will receive 20 minutes of prophylactic continuous positive airway pressure (CPAP) at 5 to 6 cm H2O, started within 5 minutes after birth. CPAP may be provided at the radiant warmer or while the infant is on the mother's chest. Participants may receive additional CPAP or other respiratory support if clinically needed.

Participants assigned to this arm will receive 20 minutes of prophylactic continuous positive airway pressure (CPAP) at 5 to 6 cm H2O, started within 5 minutes after birth. CPAP may be provided at the radiant warmer or while the infant is on the mother's chest. Participants may receive additional CPAP or other respiratory support if clinically needed.

Active Comparator: STANDARD CARE

Participants assigned to this arm will receive standard care after birth without prophylactic CPAP. CPAP or other respiratory support may be provided if clinically needed according to usual clinical care.

Participants will receive standard care after birth without prophylactic CPAP. CPAP or other respiratory support may be provided if clinically needed according to usual clinical care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of NICU admissions for respiratory support.
Time Frame: 60 minutes after birth

At the single assessment at 60 minutes after birth, an infant will be classified as "yes" if they need supplemental oxygen to reach an oxygen saturation greater than 92%, or need CPAP, or need mechanical ventilation. An infant will be classified as "no" if none of these criteria are met. Classification is based on need for respiratory support, regardless of the infant's actual location.

60 minutes after birth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Respiratory Support at 30 minutes and 24 hours after birth
Time Frame: 30 minutes and 24 hours after birth

An infant will be classified as "yes" if they need supplemental oxygen to reach an oxygen saturation greater than 92%, or need CPAP, or need mechanical ventilation. An infant will be classified as "no" if none of these criteria are met. Classification is based on need for respiratory support, regardless of the infant's actual location.

30 minutes and 24 hours after birth
PSS:NICU Overall Stress Level score
Time Frame: at hospital discharge (single measurement)

Parents will complete the PSS:NICU at infant hospital discharge to rate stress related to the NICU experience. Items are scored from 1 (not at all stressful) to 5 (extremely stressful). Using Metric 2, responses marked "not experienced" are scored as 1. For each parent, the overall score will be the mean across all PSS:NICU items (range: 1-5; maximum: 5). Mean scores and standard deviations will be reported and compared between the prophylactic CPAP and standard-care groups. Higher scores indicate greater parental stress.

at hospital discharge (single measurement)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Any breastfeeding at infant hospital discharge
Time Frame: at hospital discharge or 30 days whichever comes first (single assessment)

At hospital discharge, the infant will be classified as "Yes" if they received any breast milk, either directly at the breast or as expressed breast milk, including in combination with formula. The infant will be classified as "No" if they received no breast milk. The number and percentage classified as "Yes" and "No" will be reported by study group

at hospital discharge or 30 days whichever comes first (single assessment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

July 1, 2029

Study Registration Dates

First Submitted

October 29, 2026

First Submitted That Met QC Criteria

November 4, 2026

First Posted (Actual)

November 10, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

all data will be shared upon request after deidentification.

IPD Sharing Time Frame

after publication for one year

IPD Sharing Access Criteria

upon request to the pi

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe